S&P 500   2,628.77 (+0.08%)
DOW   22,363.71 (+0.16%)
QQQ   193.39 (+0.70%)
AAPL   259.03 (+1.66%)
FB   168.89 (+1.77%)
MSFT   160.55 (+0.20%)
GOOGL   1,168.54 (+1.94%)
AMZN   1,977.87 (+0.71%)
CGC   14.78 (+2.21%)
NVDA   269.92 (+1.63%)
BABA   195.34 (+2.13%)
MU   43.93 (-1.33%)
GE   8.04 (+1.90%)
TSLA   541.90 (+7.92%)
AMD   47.39 (-0.98%)
T   29.77 (-1.52%)
ACB   0.93 (+5.68%)
F   5.10 (+1.39%)
NFLX   376.00 (+1.36%)
BAC   22.23 (+0.86%)
GILD   75.20 (-0.96%)
PRI   89.98 (-0.80%)
DIS   100.96 (+1.16%)
S&P 500   2,628.77 (+0.08%)
DOW   22,363.71 (+0.16%)
QQQ   193.39 (+0.70%)
AAPL   259.03 (+1.66%)
FB   168.89 (+1.77%)
MSFT   160.55 (+0.20%)
GOOGL   1,168.54 (+1.94%)
AMZN   1,977.87 (+0.71%)
CGC   14.78 (+2.21%)
NVDA   269.92 (+1.63%)
BABA   195.34 (+2.13%)
MU   43.93 (-1.33%)
GE   8.04 (+1.90%)
TSLA   541.90 (+7.92%)
AMD   47.39 (-0.98%)
T   29.77 (-1.52%)
ACB   0.93 (+5.68%)
F   5.10 (+1.39%)
NFLX   376.00 (+1.36%)
BAC   22.23 (+0.86%)
GILD   75.20 (-0.96%)
PRI   89.98 (-0.80%)
DIS   100.96 (+1.16%)
S&P 500   2,628.77 (+0.08%)
DOW   22,363.71 (+0.16%)
QQQ   193.39 (+0.70%)
AAPL   259.03 (+1.66%)
FB   168.89 (+1.77%)
MSFT   160.55 (+0.20%)
GOOGL   1,168.54 (+1.94%)
AMZN   1,977.87 (+0.71%)
CGC   14.78 (+2.21%)
NVDA   269.92 (+1.63%)
BABA   195.34 (+2.13%)
MU   43.93 (-1.33%)
GE   8.04 (+1.90%)
TSLA   541.90 (+7.92%)
AMD   47.39 (-0.98%)
T   29.77 (-1.52%)
ACB   0.93 (+5.68%)
F   5.10 (+1.39%)
NFLX   376.00 (+1.36%)
BAC   22.23 (+0.86%)
GILD   75.20 (-0.96%)
PRI   89.98 (-0.80%)
DIS   100.96 (+1.16%)
S&P 500   2,628.77 (+0.08%)
DOW   22,363.71 (+0.16%)
QQQ   193.39 (+0.70%)
AAPL   259.03 (+1.66%)
FB   168.89 (+1.77%)
MSFT   160.55 (+0.20%)
GOOGL   1,168.54 (+1.94%)
AMZN   1,977.87 (+0.71%)
CGC   14.78 (+2.21%)
NVDA   269.92 (+1.63%)
BABA   195.34 (+2.13%)
MU   43.93 (-1.33%)
GE   8.04 (+1.90%)
TSLA   541.90 (+7.92%)
AMD   47.39 (-0.98%)
T   29.77 (-1.52%)
ACB   0.93 (+5.68%)
F   5.10 (+1.39%)
NFLX   376.00 (+1.36%)
BAC   22.23 (+0.86%)
GILD   75.20 (-0.96%)
PRI   89.98 (-0.80%)
DIS   100.96 (+1.16%)
Log in

NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

$474.69
+1.69 (+0.36 %)
(As of 03/31/2020 12:18 PM ET)
Today's Range
$463.80
Now: $474.69
$479.77
50-Day Range
$381.87
MA: $439.82
$494.43
52-Week Range
$271.37
Now: $474.69
$518.00
Volume431,206 shs
Average Volume1.73 million shs
Market Capitalization$52.23 billion
P/E Ratio25.71
Dividend YieldN/A
Beta0.76
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Read More
Regeneron Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.86 billion
Cash Flow$25.58 per share
Book Value$100.56 per share

Profitability

Net Income$2.12 billion

Miscellaneous

Employees8,100
Market Cap$52.23 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.


Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

How has Regeneron Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 2.1% and is now trading at $474.69. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Regeneron Pharmaceuticals?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its quarterly earnings data on Thursday, February, 6th. The biopharmaceutical company reported $7.50 EPS for the quarter, beating analysts' consensus estimates of $6.03 by $1.47. The biopharmaceutical company earned $2.17 billion during the quarter, compared to analysts' expectations of $2.10 billion. Regeneron Pharmaceuticals had a net margin of 26.91% and a return on equity of 24.14%. The company's revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period last year, the company posted $6.84 earnings per share. View Regeneron Pharmaceuticals' earnings history.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its Board of Directors has approved a stock repurchase program on Tuesday, November 5th 2019, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 2.9% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued.

What price target have analysts set for REGN?

24 Wall Street analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $550.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $460.13 in the next twelve months. This suggests that the stock has a possible downside of 3.1%. View analysts' price targets for Regeneron Pharmaceuticals.

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

Media stories about REGN stock have trended very positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutRegeneron Pharmaceuticals.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 2,558,900 shares, a drop of 11.1% from the February 27th total of 2,880,000 shares. Based on an average daily volume of 1,294,900 shares, the days-to-cover ratio is presently 2.0 days. Currently, 3.1% of the shares of the stock are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), Biogen (BIIB), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Alphabet (GOOG), Micron Technology (MU) and Broadcom (AVGO).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $474.69.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $52.23 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe. View additional information about Regeneron Pharmaceuticals.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  1,326 (Vote Outperform)
Underperform Votes:  1,244 (Vote Underperform)
Total Votes:  2,570
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel